MedPath

Evaluation of the Performance and Safety of the Aktiia Spot-check Optical Blood Pressure Monitoring Device At Wrist Against Double Auscultation

Not Applicable
Completed
Conditions
Hypertension
Interventions
Device: Device under test evaluation against references
Registration Number
NCT06565780
Lead Sponsor
Aktiia SA
Brief Summary

This study, with N = 85 participants minimum over 3 visits spread over 23 hours, has been designed to assess the accuracy and precision of the Blood Pressure and pulse rate values as generated by Aktiia.product-G0 for up to 23 hours after initialization in a cohort of subjects representative of the US population.

For the study, subjects will be asked to stay seated while measurements are taken at different timepoints.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
140
Inclusion Criteria
  1. Participants must be able to provide an informed consent to participate.
  2. Participant must be willing and able to comply with all of the study procedures and return for a day 2 visit.
  3. Participants must be 22 to 59 years of age.
  4. Participant or witness must be able to read or write in English.
Exclusion Criteria
  1. Participants with compromised circulation, injury, or physical malformation of the equipment test sites or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)
  2. Female participants who are known to be pregnant or who are trying to get pregnant confirmed by a day 1 positive urine pregnancy test unless the study participant is known to be not of child-bearing potential.
  3. Participants with known clotting disorders or currently taking a prescription blood thinner.
  4. Other known health conditions that will prevent safe participation in the study upon disclosure in Health Assessment Short Form or verbally.
  5. Participants suffering from sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including tachycardia (heart rate at rest > 120bpm) and atrial fibrillation.
  6. Participants suffering from pathologies that systematically reduce peripheral perfusion including Raynaud's disease, diabetes, renal dysfunctions (eGFR < 60mL / min / 1.73 m2), hyper- / hypothyroidism, pheochromocytoma or arteriovenous fistula.
  7. A wrist circumference below 14 cm or above 23 cm.
  8. An upper arm circumference < 22cm or > 42cm.
  9. Any subject that, in the opinion of the investigator, does not exhibit any phenotype relevant to the objectives of this study.
  10. Any condition or circumstance that, in the opinion of the investigator, may preclude study completion, interfere with accurate data collection, bias the results, by instance a subject presenting a lateral Blood Pressure difference at screening of more than 15 mmHg for the systolic and/or more than 10 mmHg for the diastolic.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Aktiia.product-G0 device under testDevice under test evaluation against referencesSubjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.
Primary Outcome Measures
NameTimeMethod
Blood pressure standard deviation of differences23 hours

The standard deviation of the differences between Aktiia.product-G0 and double auscultation blood pressure measurements.

Blood pressure mean value of differences23 hours

The mean value of the differences between Aktiia.product-G0 and double auscultation blood pressure measurements.

Secondary Outcome Measures
NameTimeMethod
Heart rate root-mean-square error23 hours

The root-mean-square difference between the Aktiia.product-G0 heart rate determinations and the reference method.

Trial Locations

Locations (1)

Parameters Research Laboratory

🇺🇸

Broomfield, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath